Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound glycyrrhiza oral solution (CGOS), also known as Brown Mixture, is a traditional combination pharmaceutical product primarily used as an antitussive and expectorant. Its standard formulation typically includes glycyrrhiza fluid extract, camphorated opium tincture, ethanol, and glycerol. The glycyrrhiza component provides anti-inflammatory and expectorant properties, while the opium tincture acts on the central nervous system to suppress cough. Recent pharmacological research has highlighted its potential therapeutic role in chronic obstructive pulmonary disease (COPD), where it appears to alleviate oxidative stress and pulmonary inflammation by inhibiting the SRC/MAPK signaling pathway. It is widely manufactured and marketed in China for the relief of respiratory symptoms associated with infections and chronic bronchitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound glycyrrhiza oral solution.